OverviewSuggest Edit

Avacta Group plc is a provider of research reagents, consumables and equipment to the life sciences and animal care markets. The Company provides research, development, production and delivery of instrumentation and services for the biopharmaceutical drug development and clinical diagnostics markets using biophysical technology. It operates through three segments: Analytical, Animal Health and Life Sciences. The Analytical segment provides tools and contract services for early stage protein characterisation and analysis for biopharmaceutical drug developers. The Animal Health segment provides tools and contract services to assist diagnosis of conditions in animals to enable faster treatment for veterinarians. The Life Sciences segment provides reagents and arrays for diagnostics, drug and biomarker discovery in biotech research and development. Its subsidiaries include Avacta Limited, Avacta Analytical Limited, Oriental Fine Foods Limited, Avacta Health Limited and others.
TypePublic
Founded2003
HQThorp Arch Estate, GB
Websiteavacta.com

Latest Updates

Employees (est.) (Sep 2017)87
Revenue (FY, 2017)£1.3 M(+48%)
Share Price (Oct 2017)£0.7

Key People/Management at Avacta Group

Alastair Smith

Alastair Smith

CEO
Tony Gardiner

Tony Gardiner

CFO
Trevor Nicholls

Trevor Nicholls

Non Executive Director
Mike Owen

Mike Owen

Senior Independent Director & Scientific Advisory Board Chairman
Alan Aubrey

Alan Aubrey

Non Executive Director
Eliot Forster

Eliot Forster

Non Executive Chairman
Show more

Avacta Group Office Locations

Avacta Group has offices in Thorp Arch Estate and London
Thorp Arch Estate, GB (HQ)
706 Avenue E West
London, GB
200 Aldersgate St
Show all (2)

Avacta Group Financials and Metrics

Avacta Group Revenue

Avacta Group's revenue was reported to be £1.28 m in FY, 2017
GBP

Revenue (FY, 2017)

1.3m

Gross profit (FY, 2017)

859.4k

Gross profit margin (FY, 2017), %

67%

Net income (FY, 2017)

(6.6m)

EBITDA (FY, 2017)

(6.9m)

EBIT (FY, 2017)

(7.9m)

Market capitalization (31-Oct-2017)

45.5m

Closing stock price (31-Oct-2017)

0.7

Cash (31-Jul-2017)

115.9k
Avacta Group's current market capitalization is £45.5 m.
GBPFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

8.7k29.8k171.5k866.8k1.3m

Revenue growth, %

475%405%

Cost of goods sold

4.0k10.5k77.0k451.1k422.5k

Gross profit

4.7k19.3k94.5k415.6k859.4k
GBPFY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

32.8k298.3k113.4k40.0k23.7k385.9k246.4k96.3k115.9k

Accounts Receivable

2.4k5.8k12.0k61.1k45.3k81.3k

Inventories

173.4k274.8k215.4k72.7k

Current Assets

35.2k304.2k118.1k100.3k214.1k1.0m1.7m2.4m2.3m
GBPFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(388.1k)(977.4k)(2.3m)(4.9m)(6.0m)(6.6m)

Income Taxes Paid

310.5k370.5k1.0m
GBPY, 2017

Revenue/Employee

14.7k

Financial Leverage

-0.3 x
Show all financial metrics

Avacta Group Online and Social Media Presence

Embed Graph

Avacta Group News and Updates

Avacta Group Plc (AVCT) Market Clinical Trials Review, H2, 2017 Strategies 2017 by Analyzing the Performance of Various Competitors

WiseGuyReports published new report, titled “Avacta Group Plc (AVCT)” Posted via Industry Today. Follow us on Twitter @IndustryToday

Avacta Group Blogs

Collaboration and Option Agreement with ADC Therapeutics

Avacta today announces that it has entered a collaboration and option agreement with ADC Therapeutics, a clinical-stage oncology-focused biotechnology company pioneering the development of highly potent and targeted antibody-drug conjugates for patients suffering from haematological malignancies and…

Affimer-enzyme-inhibitor switch sensor for rapid wash-free assays of multimeric proteins

ABSTRACT: Robust technology is required to underpin rapid point-of-care and in-field diagnostics, to improve timely decision making across broad sectors. An attractive strategy combines target recognition and signal generating elements into an “active” enzyme-switch that directly transduces target-b…

Webinar: Affimer® anti-idiotypic affinity reagents for pharmacokinetic analysis of biotherapeutics

In this webinar, Principal Assay Scientist Dr. Amanda Nicholl presented data from the recently published paper in Biotechniques, ‘Affimers as anti-idiotypic affinity reagents for pharmacokinetic analysis of biotherapeutics’. The use of anti-idiotypic Affimer reagents in this study showed a number o…

Affimers as anti-idiotypic affinity reagents for pharmacokinetic analysis of biotherapeutics

Therapeutic antibodies are the fastest growing class of drugs in the treatment of cancer, and autoimmune and inflammatory diseases that require the concomitant development of assays to monitor therapeutic antibody levels. Here, we demonstrate that the use of Affimer nonantibody binding proteins prov…

Solebury Trout European Biotech Investor Day

Presentation given by Avacta's Chief Executive Officer, Dr Alastair Smith at the European Biotech Investor Day in New York Cityon Thursday, August 1st 2019, organised by Solebury Trout.  Download presentation
Show more

Avacta Group Frequently Asked Questions

  • When was Avacta Group founded?

    Avacta Group was founded in 2003.

  • Who are Avacta Group key executives?

    Avacta Group's key executives are Alastair Smith, Tony Gardiner and Trevor Nicholls.

  • How many employees does Avacta Group have?

    Avacta Group has 87 employees.

  • What is Avacta Group revenue?

    Latest Avacta Group annual revenue is £1.3 m.

  • What is Avacta Group revenue per employee?

    Latest Avacta Group revenue per employee is £14.7 k.

  • Who are Avacta Group competitors?

    Competitors of Avacta Group include LabConnect, Proteome Sciences and Source Bioscience.

  • Where is Avacta Group headquarters?

    Avacta Group headquarters is located at 706 Avenue E West, Thorp Arch Estate.

  • Where are Avacta Group offices?

    Avacta Group has offices in Thorp Arch Estate and London.

  • How many offices does Avacta Group have?

    Avacta Group has 2 offices.